

Reviewer 3 v.1

Comments to the Author

Thank you for conducting and formulating this interesting study.

The subject of ILD and lung cancer is still illusive and no formal guidelines exist.

Major revision:

1. Authors should think about dividing their cohort in 3 groups and presenting all data in tables and text as such ; Non ILD / Non IPF ILD / IPF . Moreover from oncological perspective ED and LD should be addressed as well

2.Exclusion of resectable and palilative cases causes the issue discussed to be less generalizable - meaning we are talking only about systemic chemo/rad treatment for SCLC w/wo ILD /IPF - title of study should convey that

Minor :

1. Methods - who makes the decision regarding what kind of treatment each individual receives?

Several paragraphs have errors in grammar and terminology , examples:

Page 3 line 38-42

Page 6 - "rate of patients" should be "number of patients"

Page 7 line 17-18 "frequency " is incorrect

Please address the above mentioned remarks and submit your study for further revision